Sight Sciences CEO and leadership

Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.

Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

David Badawi is a Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the TRAB360 Trabeculotomy Instrument, the Viscoelastic Injector, the Helix Intracanalicular Scaffold, and the TearCare Dry Eye Treatment System. David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.David received a BS in Microbiology from the University of Maryland and an M.D. from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

Chief Financial Officer of Sight Sciences, Inc. He brings to Sight Sciences more than 20 years of experience leading strategic growth, financing, capital allocation and operational initiatives for growing technology companies.

Most recently, Jesse served as Chief Financial Officer and on the Board of Directors of Electric Lightwave, an over $500 million revenue, private equity sponsored telecom infrastructure business, prior to its acquisition for $1.4B in 2017.

At Electric Lightwave, Jesse led an approximately 100-person team responsible for corporate strategy, M&A, capital planning, treasury, accounting and tax, financial planning and analysis, business development, real estate and risk management. Earlier in his career, Jesse served as a Managing Director at The Blackstone Group for approximately 10 years in its mergers and acquisitions advisory practice. He holds a BS in Economics from The Wharton School at The University of Pennsylvania and an MBA from Harvard Business School.

Sam has more than 25 years of medical device start-up experience in design and operations building pre-revenue companies, and leading them through to acquisition.

Prior to joining Sight Sciences Inc., Sam served as VP of R&D and Operations at SurgRx where he led the development of EnSeal Vessel Sealing System which was purchased by Ethicon-Endo Surgery of J&J.

He also led operations at Novacept from early revenue to its acquisition by Cytyc. Sam has held various other executive and technical positions at Spineview (Expending Innovation), Arthrocare (acquired by Smith and Nephew), CardioGenesis (IPO), and Origin Medsystems (acquired by Eli Lily, later Guidant).

Before entering the medical device industry, Sam worked in aerospace at Hughes Aircraft, and Xerox Designing and Manufacturing Laser Systems.

Sam hold a BS from the University of California Irvine in Mechanical Engineering.

Chief Medical Officer (CMO) of Sight Sciences, Inc. In his role as CMO, Dr. Brown works closely with the Company's research and development team on making improvements to existing products and on new product innovation, as well as with Sight Sciences' clinical and commercial teams.

Reay H. Brown, M.D. is a board certified ophthalmologist specializing in glaucoma and cataract surgery with intraocular lens implantation.

He has been in practice in Atlanta since 1988. Dr. Brown has published more than 90 peer reviewed articles on glaucoma and cataract surgery. He has served as chairman of the ASCRS Glaucoma Committee and is currently the Glaucoma Editor of EyeWorld magazine. He recently received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia to receive this prestigious award. He received the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute) and the 2014 Innovator Award form the American Glaucoma Society. He has given many named lectures all over the world including the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. He was selected to give the Charles D. Kelman Innovator Lecture in 2017. This international award honors Dr. Kelman, the inventor of phacoemulsification, a huge step forward in successful cataract surgery outcomes. This award has only been given to 33 innovators in eye surgery since its inception in 1985.

Dr. Brown and his wife, Dr. Mary G. Lynch, a Professor at Emory, have been awarded 25 patents for new devices and instruments to improve glaucoma and cataract surgery. Their patents on trabecular bypass are the fundamental patents for several innovative devices implanted into the outflow channel of the eye. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and by a separate peer survey in Atlanta Magazine as one of the best ophthalmologist in Atlanta.

Dr. Brown earned his undergraduate degree from Harvard College Cum laude and completed medical school at the University of Michigan. He trained in ophthalmology at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident.

Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999.

Drs. Brown and Lynch have two daughters, Veronica and Annie. Rounding out their household is, Lily, a loving English Mastiff. Dr. Brown is an avid runner, enjoys playing tennis and traveling with his family.

Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.

Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

David Badawi is a Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the TRAB360 Trabeculotomy Instrument, the Viscoelastic Injector, the Helix Intracanalicular Scaffold, and the TearCare Dry Eye Treatment System. David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.David received a BS in Microbiology from the University of Maryland and an M.D. from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.

Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

David Badawi is a Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the TRAB360 Trabeculotomy Instrument, the Viscoelastic Injector, the Helix Intracanalicular Scaffold, and the TearCare Dry Eye Treatment System. David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.David received a BS in Microbiology from the University of Maryland and an M.D. from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

Chief Medical Officer (CMO) of Sight Sciences, Inc. In his role as CMO, Dr. Brown works closely with the Company's research and development team on making improvements to existing products and on new product innovation, as well as with Sight Sciences' clinical and commercial teams.

Reay H. Brown, M.D. is a board certified ophthalmologist specializing in glaucoma and cataract surgery with intraocular lens implantation.

He has been in practice in Atlanta since 1988. Dr. Brown has published more than 90 peer reviewed articles on glaucoma and cataract surgery. He has served as chairman of the ASCRS Glaucoma Committee and is currently the Glaucoma Editor of EyeWorld magazine. He recently received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia to receive this prestigious award. He received the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute) and the 2014 Innovator Award form the American Glaucoma Society. He has given many named lectures all over the world including the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. He was selected to give the Charles D. Kelman Innovator Lecture in 2017. This international award honors Dr. Kelman, the inventor of phacoemulsification, a huge step forward in successful cataract surgery outcomes. This award has only been given to 33 innovators in eye surgery since its inception in 1985.

Dr. Brown and his wife, Dr. Mary G. Lynch, a Professor at Emory, have been awarded 25 patents for new devices and instruments to improve glaucoma and cataract surgery. Their patents on trabecular bypass are the fundamental patents for several innovative devices implanted into the outflow channel of the eye. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and by a separate peer survey in Atlanta Magazine as one of the best ophthalmologist in Atlanta.

Dr. Brown earned his undergraduate degree from Harvard College Cum laude and completed medical school at the University of Michigan. He trained in ophthalmology at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident.

Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999.

Drs. Brown and Lynch have two daughters, Veronica and Annie. Rounding out their household is, Lily, a loving English Mastiff. Dr. Brown is an avid runner, enjoys playing tennis and traveling with his family.